US › Healthcare

Imunon Inc (IMNN)

US · Healthcare · Biotechnology

$1.67+5.70%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-4.2M

Profit YoY

-3.6%

EPS

$-0.84

EPS estimate

$-1.28

EPS came in at -0.84 against a street estimate of -1.28 — a beat of 34.4%.

Key statistics

Market cap

$6.6M

Forward P/E

16.8

P/B

2.00

Book value

$0.86

EPS (TTM)

$-4.52

52-week high

$7.55

52-week low

$1.47

50-day MA

$1.91

200-day MA

$3.10

Beta

1.97

Analyst view

Analysts rate Imunon Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $17.00.

Shareholding

Insiders

5.45%

Institutions

11.99%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	8.29%
Vanguard Capital Management, LLC	1.14%
Riverview Capital Advisers LLC	0.82%
Geode Capital Management, LLC	0.79%
Vanguard Fiduciary Trust Co	0.32%
HRT FINANCIAL LLC	0.29%
BlackRock Inc	0.11%
Wells Fargo & Co	0.08%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Imunon Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.